Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

StageZero Life Sciences Ltd T.SZLS

Alternate Symbol(s):  SZLSF

StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is engaged in improving the early detection and management of cancer and other chronic diseases through diagnostics and telehealth programs that provide clinical interventions to assist patients who have cancer (COC Protocol), and help patients reduce the risk of developing late-stage disease (AVRT). Its test, Aristotle, is the first mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. Aristotle uses mRNA technology to identify the molecular signatures of multiple cancer types and is built on the Company's patented technology platform, the Sentinel Principle. The Care Oncology Clinic offers a supervised treatment regimen (the COC Protocol) for people diagnosed with cancer of any type or stage. Its ColonSentry is a proprietary blood test for screening for Colorectal Cancer.


TSX:SZLS - Post by User

Bullboard Posts
Post by wildbird1on Sep 15, 2018 1:23pm
183 Views
Post# 28626271

'' Milestones ''

'' Milestones ''1) For the first time ...Thank's to JTS in the next financials Genenews will have access to a fully functional billing process for an entire quarter.

2) For the first time ...Thank's to AIM Laboratories in the next financials Genenews will have access to a very big distribution network...
PressRelease Aug 15, 2018 Jame Tripp said (Quote) Cash receipts from our billings early in Q3 showing the increase we have been expecting, and incremental testing with High Risk populations as well as the ''AIM Reps beginning''(End of Quote).
Meaning: AIM Laboratories big distribution Sale Reps have begun to sell Genenews '' Holy-Grail'' cancer tests.

3) For the first time...Genenews has on board a Chief Commercial Officer. When a CCO come on board it is usually because sales and commercial operations are expected to grow significantly.

4) For the first time...Genenews has on board a very powerfull partner '' LifeX'', whose purpose is to promote visibility and sale of Genenews cancer tests. And to top it off LifeX CEO Dr Stephan is a Geneticist by profession (PHD Scientist).
You can't ask for somebody with better credentials than a PHD Geneticist to promote genenews '' Holy-Grail '' cancer tests.

It will be very interesting to see the impact of these ''First time Milestones '' on Genenews future financials.
Bullboard Posts